(Q50551373)

English

Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden.

scientific article published on 20 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

0 references

author name string

John Teilmann Larsen

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Maria Fagerquist

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Mette Holdrup

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Bjarne Christensen

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Catarina Sigalin

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Peter M Nilsson

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

publication date

20 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Nordic Journal of Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

65

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

40-46

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

The metabolic syndrome: a glance at its history

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Schizophrenia and increased risks of cardiovascular disease

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area.

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Schizophrenia, the metabolic syndrome and diabetes

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Do stress reactions cause abdominal obesity and comorbidities?

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Effect of Acute Psychotic Stress in Nondiabetic Subjects on β-Cell Function and Insulin Sensitivity

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Metabolic syndrome

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2010.486443

21 January 2018

Identifiers

10.3109/08039488.2010.486443

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20482460

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50551373&oldid=1404531919"